Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson's disease

被引：0
|
作者：
Pinna, A.
Costa, G.
Serra, M.
Morelli, M.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
ANIMAL-MODELS; DYSKINESIA; A(2A);
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
355
引用
收藏
页码：S157 / S158
页数：2
相关论文
共 50 条
  • [41] Alterations in GABAA α1, β2 and γ2 receptor subunit gene expression in the globus pallidus in the 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease
    Chadha, A
    Duty, S
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 : U23 - U23
  • [42] 5-HT1A/1B Receptor-Mediated Effects of the Selective Serotonin Reuptake Inhibitor, Citalopram, on Sleep: Studies in 5-HT1A and 5-HT1B Knockout Mice
    Christelle Monaca
    Benjamin Boutrel
    René Hen
    Michel Hamon
    Joëlle Adrien
    Neuropsychopharmacology, 2003, 28 : 850 - 856
  • [43] 5-HT1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep:: Studies in 5-HT1A and 5-HT1B knockout mice
    Monaca, C
    Boutrel, B
    Hen, R
    Hamon, M
    Adrien, J
    NEUROPSYCHOPHARMACOLOGY, 2003, 28 (05) : 850 - 856
  • [44] Flesinoxan, a 5-HT1A receptor agonist/α1-adrenoceptor antagonist, lowers intraocular pressure in NZW rabbits
    Chidlow, G
    Cupido, A
    Melena, J
    Osborne, NN
    CURRENT EYE RESEARCH, 2001, 23 (02) : 144 - 153
  • [45] The 5-HT1A receptor agonist flesinoxan shares discriminative stimulus properties with some 5-HT2 receptor antagonists
    Herremans, AHJ
    Van der Heyden, JAM
    Van Drimmelen, M
    Olivier, B
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1999, 64 (02) : 389 - 395
  • [46] 5-HT2C receptor sensitivity after chronic paroxetine administration in the presence or absence of the 5-HT1A receptor antagonist WAY100635
    Starr, KR
    Duxon, MS
    Upton, N
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 : 473 - 473
  • [47] SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist:: In vitro and in vivo neuropharmacology
    Glennon, J
    McCreary, AC
    Ronken, E
    Siarey, R
    Hesselink, MB
    Feenstra, R
    Van Vliet, B
    Long, SK
    Kruse, CG
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S277 - S277
  • [48] Preclinical pharmacology of B-20991, a 5-HT1A receptor agonist with anxiolytic activity
    Beneytez, ME
    Rodriguez, MLL
    Rosado, ML
    Morcillo, MJ
    Orensanz, L
    Fuentes, JA
    Manzanares, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 344 (2-3) : 127 - 135
  • [49] The selective 5-HT1A receptor antagonist WAY-100635 inhibits neuronal activity of the ventromedial prefrontal cortex in a rodent model of Parkinson's disease
    Cao J.
    Liu J.
    Zhang Q.-J.
    Wang T.
    Wang S.
    Han L.-N.
    Li Q.
    Neuroscience Bulletin, 2007, 23 (6) : 315 - 322
  • [50] Partial 5-HT1A receptor agonist activity by the 5-HT2C receptor antagonist SB 206,553 is revealed in rats spinalized as neonates
    Shumsky, JS
    Kao, T
    Amato, N
    Simansky, K
    Murray, M
    Moxon, KA
    EXPERIMENTAL NEUROLOGY, 2005, 191 (02) : 361 - 365
12345